A new obesity admiration drug, Acomplia (rimonabant), makes patients lose 10% of their body coefficient, according to clinical trials carried out by Sanofi-Aventis, the bag largest pharmaceutical band in the domain.
Sanofi-Aventis are hoping to have this drug on the sales outlet if all goes well.
According to the trials, patients on a 20mg dose lost 8.6kg while those on a medicine lost 2.3kg. This latest run confirms a previous rumination (March 2004).
11.55% of the patients on the affliction had to drop out due to sickness and dizziness. There were no indications of cardiovascular or mental side effects, said the researchers.
If all goes well, said Sanofi-Aventis, the drug could be on the retail store in 2006.